Carla Visseren-Grul

Carla Visseren-Grul

Auto-generated profile, based on publicly available information

Carla Visseren-Grul

Eli Lilly and Company, 3528 BJ Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
DFDean Fennell
Dean Fennell
YSY. Summers
Y. Summers
JCJacques Cadranel
Jacques Cadranel
TBT. Benepal
T. Benepal
DCD.C. Christoph
D.C. Christoph
DFD. Ferry
D. Ferry

12 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
XLXiuning Le
Xiuning Le
CMCliff Molife
Cliff Molife
MLMark S. Leusch
Mark S. Leusch
MRMaria Teresa Rizzo
Maria Teresa Rizzo
PPPatrick Marshall Peterson
Patrick Marshall Peterson
CVCarla Visseren-Grul
Carla Visseren-Grul
TP53 co-mutations have shown association with poor prognosis in various solid tumors. For EGFR-mutated advanced non-small cell lung cancer (aNSCLC), conflicting results exist regarding its impact on survival. Clinical outcomes and genomic data were obtained retrospectively from the real-world (rw) de-identified clinicogenomic database. Patients who initiated therapy for EGFR-mutated aNSCLC between January 2014 and December 2020 were identified. Clinical outcomes were evaluated by TP53-mutational status. In 356 eligible EGFR-mutated aNSCLC patients (median age 68 years), 210 (59.0%) had TP53 co-mutation and 146 (41.0%) had TP53 wild-type tumor. Unadjusted analysis showed significantly shorter survival in patients with TP53 co-mutation versus TP53 wild-type (rw progression-free survival [rwPFS]: HR = 1.4, 95% CI 1.1–1.9, p = 0.0196; overall survival [OS]: HR = 1.6, 95% CI 1.1–2.2, p = 0.0088). Multivariable analysis confirmed independent association between TP53 co-mutation and worse rwPFS (HR = 1.4, 95% CI 1.0–0.9, p = 0.0280) and OS (HR = 1.4, 95% CI 1.0–2.0, p = 0.0345). Directionally consistent findings were observed for response rates, and subgroups by EGFR-activating mutation and first-line (1 L) therapy, with more pronounced negative effect in 1 L EGFR-TKI subgroup. TP53 co-mutations negatively affected survival in patients with EGFR-mutated aNSCLC receiving standard 1 L therapy in real-world practice.

19 April 2021 in Future Oncology
Verified
Journal Article
Open access
KWKatherine B Winfree
Katherine B Winfree
CMCliff Molife
Cliff Molife
PPPatrick M Peterson
Patrick M Peterson
YCYongmei Chen
Yongmei Chen
CVCarla M Visseren-Grul
Carla M Visseren-Grul
ADAnastasios Dimou
Anastasios Dimou
Aim: To estimate real-world (rw) outcomes for first-line therapy in patients with advanced EGF receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), focusing on specific mutation types. Patie...

20 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GSGiorgio V. Scagliotti
Giorgio V. Scagliotti
UPUgo Pastorino
Ugo Pastorino
JVJ. F. Vansteenkiste
J. F. Vansteenkiste
LSLorenzo Spaggiari
Lorenzo Spaggiari
Francesco FaccioloFrancesco Facciolo
Francesco Facciolo
VTV. Torri
V. Torri
7508 Background: This phase III study tested the hypothesis whether 3 preoperative cycles of gemcitabine-cisplatin followed by radical surgery provides a reduction in the risk of progression compared with surgery alone in patients (pts) with stage IB- IIIA NSCLC. Methods: Chemotherapy naive pts with clinical stage T2N0, T1–2N1, or T3N0–1 received either preoperatively cisplatin (75 mg/m2, day 1) and gemcitabine (1,250 mg/m2, days 1&8), q3week followed by surgery (C+S) or surgery alone (S). In 2004 the enrollment was closed early after the inclusion of 270 out of 700 planned pts because investigators felt it unethical to complete the study treating patients with surgery alone due to positive adjuvant studies. Results: From September 2000 to December 2004, 141 pts were randomized to S and 129 to C+S. Median age was 63/61 years, and most of pts were male (89%/78%). Stage IB/IIA disease was reported in 55% and 46%, respectively. The commonest histology was squamous cell carcinoma (45%/37%) followed by adenocarcinoma (30%/33%). In C+S arm, 86% of patients received all 3 cycles of chemotherapy. Surgery was performed in 96% of pts in the S arm and in 85% of C+S arm. Response rate to chemotherapy was 35% (95%CI 26–44). Progression of neoplastic disease during chemotherapy was reported in 5.5% of pts. As of November 2007, 55% of the progressions occurred. The 3-yr progression-free survival (PFS) rate was 48% in S (95%CI: 38% - 56%) and 53% in C+S (95%CI: 43% - 61%) (p= 0.11, log-rank test). The overall 3-year survival rate was 60% in S (95% CI: 51% - 68%) and 67% in C+S (95% CI 58% - 75%) (p= 0.053). Eight deaths related to study drug or procedure were observed during the study (6 in S, 2 in C+S). Conclusions: This prematurely closed phase III study in early-stage NSCLC indicates the efficacy outcome estimates in the range of those reported from other neoadjuvant trials in the same setting of patients.

3 October 2013 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
RLRohit Lal
Rohit Lal
NBNawel Bourayou
Nawel Bourayou
GHGunnar Hillerdal
Gunnar Hillerdal
MNMarianne Nicolson
Marianne Nicolson
AVAnders Vikstrom
Anders Vikstrom
CVCarla Visseren-Grul
Carla Visseren-Grul
Background: Home-based care in oncology is mainly reserved for patients at the end of life. Regulations regarding home delivery of cytotoxics differ across Europe, with a notable lack of practice guidelines in most countries. This has led to a lack of data addressing the feasibility of home-based administration of cytotoxic chemotherapy. In advanced non-squamous non-small cell lung cancer, pemetrexed is approved as maintenance therapy after first-line chemotherapy. In this setting, patients have the potential to be treated long-term with maintenance therapy, which, in the absence of unacceptable toxicity, is continued until disease progression. The favourable safety profile of pemetrexed and the ease of its administration by 10-minute intravenous infusion every 3 weeks make this drug a suitable candidate for administration in a home setting. Methods: Literature and regulations relevant to the home-based delivery of cytotoxic therapy were reviewed, and a phase II feasibility study of home administration of pemetrexed maintenance therapy was designed. At least 50 patients with advanced non-squamous non-small cell lung cancer, Eastern Cooperative Oncology Group performance status 0–1 and no progressive disease after four cycles of platinum-based first-line therapy are required to allow investigation of the feasibility of home-based administration of pemetrexed maintenance therapy (500 mg/m2 every 3 weeks until progressive disease or unacceptable toxicity). Feasibility is being assessed as adherence to the home-based administration process (primary endpoint), patient safety, impact on patients’ quality of life, patient and physician satisfaction with home care, and healthcare resource use and costs. Enrolment of patients from the UK and Sweden, where home-based care is relatively well developed, commenced in December 2011. Discussion: This feasibility study addresses an important aspect of maintenance therapy, that is, patient comfort during protracted home-based chemotherapy. The study design requires unusual methodology and specific logistics to address outcomes relevant to the home-delivery approach. This article presents a study design that offers a novel and reproducible model for home-based chemotherapy, and provides an up-to-date overview of the literature regarding this type of treatment. Trial registration: ClinicalTrials.gov: NCT01473563